Exendin-4 reduces glycemia by increasing liver glucokinase activity: An insulin independent effect

Pharmacological Reports

Volumn 64, Issue 1, 2012, Pages 140-149

  Dhanesha, Nirav ^a   Joharapurkar, Amit ^a   Shah, Gaurang ^b   Dhote, Vipin ^a   Kshirsagar, Samadhan ^a   Bahekar, Rajesh ^a   Jain, Mukul ^a  

^a ZYDUS RESEARCH CENTRE   (India)

^b K B INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

Author keywords

Exendin 4; Glucokinase; Hepatic insulin resistance; Liver

Indexed keywords

CYCLIC AMP; EXENDIN 4; EXENDIN 9 39; GLUCAGON LIKE PEPTIDE; GLUCOKINASE; GLUCOSE; GLYCOGEN; INSULIN; ISOBUTYLMETHYLXANTHINE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GLYCOGEN LIVER LEVEL; IN VIVO STUDY; INSULIN LIKE ACTIVITY; INSULIN RESISTANCE; INSULIN RESPONSE; MALE; MOUSE; NONHUMAN; SINGLE DRUG DOSE; UPREGULATION;

EID: 84862182799     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70740-5     Document Type: Article

References (38)

1. Acitores A, Gonzalez N, Sancho V, Valverde I, Villanueva-Penacarrillo ML: Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle. J Endocrinol. 2004, 180, 389-398. (Pubitemid 38443391)
2. Alcántara AI, Morales M, Delgado E, López-Delgado MI, Clemente F, Luque MA, Malaisse WJ et al.: Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle. Arch Biochem Biophys, 1997, 341, 1-7. (Pubitemid 27198024)
3. Arnes L, Moreno P, Nuche-Berenguer B, Valverde I, Villanueva-Penacarrillo M: Effect of exendin-4 treatment upon glucose uptake parameters in rat liver and muscle, in normal and type 2 diabetic state. Regul Pept, 2009, 153, 88-92.
4. Aviv V, Meivar-Levy I, Rachmut IH, Rubinek T, Mor E, Ferber S: Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process. J Biol Chem, 2009, 284, 33509-33520.
5. Bavenholm PN, Pigon J, Ostenson CG, Efendic S: Insulin sensitivity of suppression of endogenous glucose production is the single most important determinant of glucose tolerance. Diabetes, 2001, 50, 1449-1454. (Pubitemid 32500179)
6. Berry MN, Friend DS: High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study. J Cell Biol, 1969, 43, 506-520.
7. Bonadonna RC, Heise T, Arbet-Engels C, Kapitza C, Avogaro A, Grimsby J, Zhi J et al.: Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab, 2010, 95, 5028-5036.
8. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW: Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest, 1994, 93, 2263-2266. (Pubitemid 24143111)
9. Dardevet D, Moore MC, Neal D, DiCostanzo CA, Snead W, Cherrington AD: Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region. Am J Physiol Endocrinol Metab, 2004, 287, E75-E81. (Pubitemid 38856285)
10. Davis RC, Castellani LW, Hosseini M, Ben-Zeev O, Mao HZ, Weinstein MM, Jung DY et al.: Early hepatic insulin resistance precedes the onset of diabetes in obese C57BLKS-db/db mice. Diabetes, 2010, 59, 1616-1625.
11. DeFronzo RA, Prato SD: Insulin resistance and diabetes mellitus. J Diabetes Complications, 1996, 10, 243-245. (Pubitemid 26326903)
12. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA: Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology, 2006, 43, 173-181. (Pubitemid 43733604)
13. Drucker DJ: The biology of incretin hormones. Cell Metab, 2006, 3, 153-165.
14. Egan JM, Meneilly GS, Habener JF, Elahi D: Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab, 2002, 87, 3768-3773. (Pubitemid 34879525)
15. Egan JM, Montrose-Rafizadeh C, Wang Y, Bernier M, Roth J: Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology, 1994, 135, 2070-2075. (Pubitemid 24363904)
16. Elahi D, Egan JM, Shannon RP, Meneilly GS, Khatri A, Habener JF, Andersen DK: GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity (Silver Spring), 2008, 16, 1501-1509. (Pubitemid 351915102)
17. Eng J, KleinmanWA, Singh L, Singh G, Raufman JP: Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem, 1992, 267, 7402-7405.
18. Gedulin BR, Smith PA, Jodka CM, Chen K, Bhavsar S, Nielsen LL, Parkes DG, Young AA: Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int J Pharm, 2008, 356, 231-238.
19. Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA: Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology, 2010, 51, 1584-1592.
20. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med, 1992, 326, 1316-1322.
21. Hansen BF, Jensen P, Nepper-Christensen E, Skjolstrup B: Effects of glucagon-like peptide-1 (7-36)amide on insulin stimulated rat skeletal muscle glucose transport. Acta Diabetol, 1998, 35, 101-103. (Pubitemid 28403241)
22. Ionut V, Zheng D, Stefanovski D, Bergman RN: Exenatide can reduce glucose independent of islet hormones or gastric emptying. Am J Physiol Endocrinol Metab, 2008, 295, E269-E277.
23. Jeng CY, Sheu WH, Fuh MM, Chen YD, Reaven GM: Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM. Diabetes, 1994, 43, 1440-1444.
24. Kieffer TJ, Habener JF: The glucagon-like peptides. Endocr Rev, 1999, 20, 876-913. (Pubitemid 30647076)
25. Lopez-Delgado MI, Morales M, Villanueva-Penacarrillo ML, Malaisse WJ, Valverde I: Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase a in hepatocytes from normal and diabetic rats. Endocrinology, 1998, 139, 2811-2817. (Pubitemid 28512390)
26. Łabuzek K, Liber S, Gabryel B, Okopień B:Metformin has adenosine-monophosphate activated protein kinase (AMPK)-independent effects on LPS-stimulated rat primary microglial cultures. Pharmacol Rep, 2010, 62, 827-848.
27. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S et al.: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med, 1998, 128, 176-185. (Pubitemid 28078198)
28. Matschinsky FM: Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes, 1996, 45, 223-241.
29. Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Finegood DT, Elahi D: Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care, 2001, 24, 1951-1956. (Pubitemid 33716507)
30. Natali A, Ferrannini E: Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia, 2006, 49, 434-441. (Pubitemid 43277865)
31. Nielsen LL, Young AA, Parkes DG: Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept, 2004, 117, 77-88. (Pubitemid 38045329)
32. Orskov L, Holst JJ, Møller J, Orskov C, Møller N, Alberti KG, Schmitz O: GLP-1 does not not acutely affect insulin sensitivity in healthy man. Diabetologia, 1996, 39, 1227-1232.
33. Roehrig KL, Allred JB: Direct enzymatic procedure for the determination of liver glycogen. Anal Biochem, 1974, 58, 414-421.
34. Ryan AS, Egan JM, Habener JF, Elahi D: Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab, 1998, 83, 2399-2404. (Pubitemid 28503037)
35. Shalev A, Ninnis R, Keller U: Effects of glucagon-like peptide 1 (7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men. Horm Res, 1998, 49, 221-225. (Pubitemid 28165739)
36. Spence JT: Levels of translatable mRNA coding for rat liver glucokinase. J Biol Chem, 1983, 258, 9143-9146.
37. Valverde I, Morales M, Clemente F, López-Delgado MI, Delgado E, Perea A, Villanueva-Peñacarrillo ML: Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett, 1994, 349, 313-316. (Pubitemid 24263284)
38. Wang Q, Brubaker PL: Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia, 2002, 45, 1263-1273.